Amgen Third-Quarter Sales Rise 8% on Cholesterol and Cancer Drug Demand
Amgen said third-quarter sales rose 8%, led by demand for Repatha, Imdelltra and Uplizna.
By Deena BeasleyAmgen NASDAQ:AMGN on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug Repatha and newer medicines Imdelltra for lung cancer and rare disease therapy Uplizna, as the company moves ahead with development of its high-profile experimental weight-loss drug Mar…